Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  American Journal of Hypertension

• Publication date

  2012-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/ajh.2011.245PMID 22258336
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mineralocorticoid Receptor Blockade in Chronic Kidney Disease

  2012cited by this paper
• Resistant hypertension, obstructive sleep apnoea and aldosterone

  2012cited by this paper
• What is the prevalence of resistant hypertension in the United States?

  2012cited by this paper
• Cell membrane-associated mineralocorticoid receptors? New evidence.

  2011cited by this paper
• Resistant Hypertension and Sleep Apnea: Pathophysiologic Insights and Strategic Management

  2011cited by this paper
• Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway.

  2011cited by this paper
• Obstructive Sleep Apnea: The Most Common Secondary Cause of Hypertension Associated With Resistant Hypertension

  2011cited by this paper
• Mineralocorticoid Receptor Blockade in Chronic Kidney Disease

  2011cited by this paper
• Guidelines for the diagnosis and treatment of primary aldosteronism--the Japan Endocrine Society 2009.

  2011cited by this paper
• Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease.

  2011cited by this paper
• GPR30 Expression Is Required for the Mineralocorticoid Receptor–Independent Rapid Vascular Effects of Aldosterone

  2011cited by this paper
• Positive relationship of sleep apnea to hyperaldosteronism in an ethnically diverse population

  2011cited by this paper
• Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease.

  2011cited by this paper
• GPR30, mineralocorticoid receptors, and the rapid vascular effects of aldosterone.

  2011cited by this paper
• Coactivation of SF-1-mediated transcription of steroidogenic enzymes by Ubc9 and PIAS1.

  2011cited by this paper
• Eplerenone in patients with systolic heart failure and mild symptoms.

  2011cited by this paper
• The Role of Aldosterone in the Metabolic Syndrome

  2011cited by this paper
• Prevalence of Resistant Hypertension in the United States, 2003–2008

  2011cited by this paper
• Are melatonin and its receptor agonist specific antihypertensive modulators of resistant hypertension caused by disrupted circadian rhythm?

  2011cited by this paper
• Management of blood pressure in patients with diabetes.

  2011cited by this paper
• Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment.

  2010cited by this paper
• Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome.

  2010cited by this paper
• Modulation of transcription factor function by O-GlcNAc modification.

  2010cited by this paper
• The Impact of Macrophage Insulin Resistance on Advanced Atherosclerotic Plaque Progression [2010;106:58–67] The RAGE Axis: A Fundamental Mechanism Signaling Danger to the Vulnerable Vasculature [2010;106:842–853] The Promise of Cell-Based Therapies for Diabetic Complications: Challenges and Solution

  2010cited by this paper
• Activation of protein kinase C isoforms and its impact on diabetic complications.

  2010cited by this paper
• Obesity-related hypertension: epidemiology, pathophysiology, and clinical management.

  2010cited by this paper
• Salt-sensitive hypertension in circadian clock–deficient Cry-null mice involves dysregulated adrenal Hsd3b6

  2010cited by this paper
• Elevated Mineralocorticoid Receptor Activity in Aged Rat Vascular Smooth Muscle Cells Promotes a Proinflammatory Phenotype via Extracellular Signal-Regulated Kinase 1/2 Mitogen-Activated Protein Kinase and Epidermal Growth Factor Receptor–Dependent Pathways

  2010cited by this paper
• Cyclin-dependent kinase 5 modulates the transcriptional activity of the mineralocorticoid receptor and regulates expression of brain-derived neurotrophic factor.

  2010cited by this paper
• The prevalence of metabolic syndrome and its components in two main types of primary aldosteronism

  2010cited by this paper
• Aldosterone blockade in chronic kidney disease: can it improve outcome?

  2010cited by this paper
• Aldosterone in the Pathogenesis of Chronic Kidney Disease and Proteinuria

  2010cited by this paper
• O-GlcNAc modification, insulin signaling and diabetic complications.

  2010cited by this paper
• NF-YC Functions as a Corepressor of Agonist-bound Mineralocorticoid Receptor*

  2010cited by this paper
• Position paper: Rapid responses to steroids: current status and future prospects.

  2010cited by this paper
• The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family.

  2010cited by this paper
• Adipokines and cardiometabolic profile in primary hyperaldosteronism.

  2010cited by this paper
• Mineralocorticoid Receptor Antagonists and the Metabolic Syndrome

  2010cited by this paper
• Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.

  2009cited by this paper
• Osmotic stress regulates mineralocorticoid receptor expression in a novel aldosterone-sensitive cortical collecting duct cell line.

  2009cited by this paper
• The mineralocorticoid receptor and its coregulators.

  2009cited by this paper
• Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.

  2009cited by this paper
• Inhibitory effects of a dihydropyridine calcium channel blocker on renal injury in aldosterone-infused rats

  2009cited by this paper
• Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research

  2009cited by this paper
• New aspects of rapid aldosterone signaling.

  2009cited by this paper
• EGF receptor as a drug target in arterial hypertension.

  2009cited by this paper
• The role of mineralocorticoid receptor expression in brain remodeling after cerebral ischemia

  2009cited by this paper
• Spironolactone Reduces Severity of Obstructive Sleep Apnea in Patients with Resistant Hypertension: a Preliminary Report

  2009cited by this paper
• Aldosterone-receptor antagonism in hypertension

  2009cited by this paper
• Narrative Review: The Emerging Clinical Implications of the Role of Aldosterone in the Metabolic Syndrome and Resistant Hypertension

  2009cited by this paper
• Targeting the protein kinase C family in the diabetic kidney: lessons from analysis of mutant mice

  2009cited by this paper
• Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline.

  2008cited by this paper
• A Number of Marketed Dihydropyridine Calcium Channel Blockers Have Mineralocorticoid Receptor Antagonist Activity

  2008cited by this paper
• The role of mineralocorticoid receptor expression in brain remodeling after cerebral ischemia.

  2008cited by this paper
• Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease

  2008cited by this paper
• Aldosterone and Metabolic Syndrome: Is Increased Aldosterone in Metabolic Syndrome Patients an Additional Risk Factor?

  2008cited by this paper
• Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review.

  2008cited by this paper
• Aldosterone-to-renin ratio as a screening test for primary aldosteronism--the Dutch ARRAT Study.

  2008cited by this paper
• Nongenotropic aldosterone effects and the EGFR: interaction and biological relevance.

  2008cited by this paper
• Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

  2008cited by this paper
• Cardiovascular outcomes in patients with primary aldosteronism after treatment.

  2008cited by this paper
• Deletion of Protein Kinase C-β Isoform In Vivo Reduces Renal Hypertrophy but Not Albuminuria in the Streptozotocin-Induced Diabetic Mouse Model

  2007cited by this paper
• The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology

  2007cited by this paper
• Human adipocytes induce an ERK1/2 MAP kinases-mediated upregulation of steroidogenic acute regulatory protein (StAR) and an angiotensin II — sensitization in human adrenocortical cells

  2007cited by this paper
• Aldosterone-induced EGFR expression: interaction between the human mineralocorticoid receptor and the human EGFR promoter.

  2007cited by this paper
• Association of Adrenal Steroids With Hypertension and the Metabolic Syndrome in Blacks

  2007cited by this paper
• The role of protein kinase C activation and the vascular complications of diabetes.

  2007cited by this paper
• Non-classical actions of the mineralocorticoid receptor: misuse of EGF receptors?

  2007cited by this paper
• The incidence and implications of aldosterone breakthrough

  2007cited by this paper
• Resistant hypertension and aldosteronism

  2007cited by this paper
• Coactivation of the N-terminal Transactivation of Mineralocorticoid Receptor by Ubc9*

  2007cited by this paper
• Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome.

  2006cited by this paper
• Autosomal dominant pseudohypoaldosteronism type 1: mechanisms, evidence for neonatal lethality, and phenotypic expression in adults.

  2006cited by this paper
• Long-term renal outcomes in patients with primary aldosteronism.

  2006cited by this paper
• Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy.

  2006cited by this paper
• Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus.

  2006cited by this paper
• Plasma Aldosterone Is Independently Associated With the Metabolic Syndrome

  2006cited by this paper
• Aldosterone and refractory hypertension: a prospective cohort study.

  2006cited by this paper
• Renal Damage in Primary Aldosteronism: Results of the PAPY Study

  2006cited by this paper
• Prevalence and characteristics of the metabolic syndrome in primary aldosteronism.

  2006cited by this paper
• Mineralocorticoid Receptor Antagonism Attenuates Cardiac Hypertrophy and Failure in Low-Aldosterone Hypertensive Rats

  2006cited by this paper
• Ubc9 and Protein Inhibitor of Activated STAT 1 Activate Chicken Ovalbumin Upstream Promoter-Transcription Factor I-mediated Human CYP11B2 Gene Transcription*

  2005cited by this paper
• Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism.

  2005cited by this paper
• The effect of ruboxistaurin on nephropathy in type 2 diabetes.

  2005cited by this paper
• Increased Expression of Mineralocorticoid Effector Mechanisms in Kidney Biopsies of Patients With Heavy Proteinuria

  2005cited by this paper
• The mineralocorticoid receptor: a journey exploring its diversity and specificity of action.

  2005cited by this paper
• Proteasome‐Mediated Mineralocorticoid Receptor Degradation Attenuates Transcriptional Response to Aldosterone

  2004cited by this paper
• Epoxy-Keto Derivative of Linoleic Acid Stimulates Aldosterone Secretion

  2004cited by this paper
• Serum aldosterone and the incidence of hypertension in nonhypertensive persons.

  2004cited by this paper
• Ubc9 interacts with chicken ovalbumin upstream promoter-transcription factor I and represses receptor-dependent transcription.

  2004cited by this paper
• Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

  2003cited by this paper
• Aldosterone blockade in patients with acute myocardial infarction.

  2003cited by this paper
• Efficacy of low-dose spironolactone in subjects with resistant hypertension.

  2003cited by this paper
• Eplerenone , a Selective Aldosterone Blocker , in Patients with Left Ventricular Dysfunction after Myocardial Infarction

  2003cited by this paper
• Human adipocytes secrete mineralocorticoid-releasing factors

  2003cited by this paper
• Nuclear Receptors and Co-Regulators in Adrenal Tumors

  2003cited by this paper
• Suppression of TSH in Congenital Hypothyroidism Is Significantly Related to Serum Levels and Dosage of Thyroxine

  2003cited by this paper
• Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy.

  2000cited by this paper
• The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

  2000cited by this paper
• The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

  1999cited by this paper

• The Influence of Sex and Hormones on Organelle Stress in Kidney Injury: Insights from Preclinical Models

  2026cites this paper
• Aldosterone-mineralocorticoid receptor interactions: new insights and therapeutic perspectives in primary aldosteronism.

  2026cites this paper
• Pre-treatment estimated glomerular filtration rate trajectory modifies the renoprotective effect of finerenone in patients with chronic kidney disease associated with type 2 diabetes

  2026cites this paper
• Relationship between blood pressure level and activity of renin-aldosterone axis in patients with essential hypertension-a retrospective study.

  2026cites this paper
• The conservative-challenging paradigm of antihypertensive therapy in JSH2025: a comparative perspective with contemporary Western guidelines.

  2026cites this paper
• Baxdrostat for uncontrolled and resistant hypertension: rationale and design of the Phase 3 clinical trials BaxHTN, BaxAsia, and Bax24

  2025cites this paper
• Efficacy and Safety of Esaxerenone for Essential Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2025cites this paper
• Esaxerenone Attenuates Atherogenesis and Vascular Dysfunction in Apolipoprotein E-Deficient Mice.

  2025cites this paper
• Unexplained Hypokalemia in a Patient With Obesity Harboring an Armadillo Repeat-Containing 5 (ARMC5) Gene Variant: A Case Report

  2025cites this paper
• Esaxerenone Attenuates Cardiac Hypertrophy in a Pressure Overload Model in Mice.

  2025cites this paper
• Esaxerenone improves the blood pressure and metabolic parameters of hypertensive subjects with diabetes

  2025cites this paper
• Glucocorticoids: The culprit behind metabolic disorders in primary Aldosteronism? A narrative review

  2025cites this paper
• Huangkui capsule, an extract from Abelmoschus manihot (L.) medic, inhibits adrenal aldosterone synthesis and renal ERK/EGR1 pathway in the treatment of diabetic kidney disease.

  2025cites this paper
• Urinary cortisol-to-cortisone ratio levels modify the association between diabetes and hypertension: a cross-sectional study of 6931 older adults

  2025cites this paper
• Retrospective analysis of influences of sacubitril/valsartan in patients with diabetes with poorly controlled blood pressure in Japan

  2025cites this paper
• Prediction of endogenous mineralocorticoid receptor activity by depressor effects of mineralocorticoid receptor antagonists in patients with primary aldosteronism

  2024cites this paper
• Indoxyl Sulfate and Its Potential Role in Mineralocorticoid Receptor Transactivation in Chronic Kidney Disease

  2024cites this paper
• Long-term effects of esaxerenone in patients with type 2 diabetes, diabetic kidney disease, and hypertension (JDDM77)

  2024cites this paper
• Antihypertensive effects and changes in extracellular water content by mineralocorticoid receptor antagonists in patients with primary aldosteronism

  2024cites this paper
• Treatment with a mineralocorticoid receptor blocker esaxerenone on top of the first-line therapy: promise in uncontrolled hypertension

  2024cites this paper
• Home blood pressure-lowering effect of esaxerenone versus trichlormethiazide for uncontrolled hypertension: a predefined subanalysis of the EXCITE-HT randomized controlled trial by basal calcium channel blocker versus angiotensin receptor blocker

  2024cites this paper
• Prevalence of unilateral hyperaldosteronism in primary aldosteronism: impact of a novel chemiluminescent immunoassay for measuring plasma aldosterone in Japan

  2024cites this paper
• Will esaxerenone be added to the antihypertensive treatment strategy of practicing physicians as a second-line antihypertensive drug?

  2024cites this paper
• Mineralocorticoid receptor overactivation in diabetes mellitus: role of O-GlcNAc modification

  2024cites this paper
• Serum Soluble Urokinase Plasminogen Activator Receptor Levels in Resistant Hypertension

  2024cites this paper
• Screening and diagnosis of primary aldosteronism. Consensus document of all the Spanish Societies involved in the management of primary aldosteronism

  2024cites this paper
• Nighttime home blood pressure lowering effect of esaxerenone in patients with uncontrolled nocturnal hypertension: the EARLY-NH study

  2023cites this paper
• Renoprotective Effects of Mineralocorticoid Receptor Antagonists Against Diabetic Kidney Disease

  2023cites this paper
• Exposure-response analysis of the efficacy and safety of esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with or without diabetic kidney disease.

  2023cites this paper
• Effects of esaxerenone on blood pressure, urinary albumin excretion, serum levels of NT-proBNP, and quality of life in patients with primary aldosteronism

  2023cites this paper
• Utility of 18-hydroxycortisol and 18-oxocortisol: potential markers of aldosterone-producing adenomas

  2023cites this paper
• Rationale and design of an investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized trial to evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in type 2 diabetes and chronic kidney disease (FIVE-STAR)

  2023cites this paper
• ALDOSTERONE Mineralocorticoid Receptor (MR)-associated Hypertension: Over-activation of MR by 'Greedy Kidney and Guts' for salt and sugar

  2023cites this paper
• Aldosterone: Essential for Life but Damaging to the Vascular Endothelium

  2023cites this paper
• Esaxerenone for nocturnal hypertension and possible future direction for treatment of hypertension-cardiovascular-kidney comorbidity

  2023cites this paper
• Associations of diabetic retinopathy severity with high ambulatory blood pressure and suppressed plasma renin levels.

  2023cites this paper
• Recent understandings about hypertension management in type 2 diabetes: What are the roles of SGLT2 inhibitor, GLP-1 receptor agonist, and finerenone?

  2023cites this paper
• Recent progress in the diagnosis and treatment of primary aldosteronism

  2023cites this paper
• Mineralocorticoid Receptor Antagonists for Preventing Chronic Kidney Disease Progression: Current Evidence and Future Challenges

  2023cites this paper
• Fat mass: the most sensitive predictor of persistent hypertension in unilateral primary aldosteronism

  2023cites this paper
• Visceral fat: a bad companion for mineralocorticoid receptor overactivation

  2023cites this paper
• Impact of a change to a novel chemiluminescent immunoassay for measuring plasma aldosterone on the diagnosis of primary aldosteronism.

  2023cites this paper
• Aldosterone breakthrough from a pharmacological perspective

  2022cites this paper
• Adrenal ablation therapy for unilateral primary aldosteronism: pros and cons

  2022cites this paper
• Reduction of Proteinuria in a Patient With Primary Aldosteronism by Angiotensin II Receptor Blocker Administration

  2022cites this paper
• Mechanisms of mineralocorticoid receptor-associated hypertension in diabetes mellitus: the role of O-GlcNAc modification

  2022cites this paper
• Nephrons, podocytes and chronic kidney disease: Strategic antihypertensive therapy for renoprotection

  2022cites this paper
• Dex modulates the balance of water-electrolyte metabolism by depressing the expression of AVP in PVN

  2022cites this paper
• Update on Hypertension Research in 2021

  2022cites this paper
• Clinical effect of nonsteroidal mineralocorticoid receptor (MR) antagonists in the treatment of diabetic kidney disease: expectations as a new therapeutic strategy

  2022cites this paper
• The mineralocorticoid receptor signal could be a new molecular target for the treatment of diabetic retinal complication

  2022cites this paper
• Re-Assessment of the Oral Salt Loading Test Using a New Chemiluminescent Enzyme Immunoassay Based on a Two-Step Sandwich Method to Measure 24-Hour Urine Aldosterone Excretion

  2022cites this paper
• Lysine-specific demethylase 1 as a corepressor of mineralocorticoid receptor

  2022cites this paper
• “Greedy Organs Hypothesis” for sugar and salt in the pathophysiology of non-communicable diseases in relation to sodium-glucose co-transporters in the intestines and the kidney

  2022cites this paper
• miR-324-5p and miR-30c-2-3p Alter Renal Mineralocorticoid Receptor Signaling under Hypertonicity

  2022cites this paper
• Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021.

  2022cites this paper
• Safety and efficacy of esaxerenone in Japanese hypertensive patients with heart failure with reduced ejection fraction: A retrospective study

  2021cites this paper
• The mineralocorticoid receptor blocker spironolactone lowers plasma interferon-γ and interleukin-6 in patients with type 2 diabetes and treatment-resistant hypertension

  2021cites this paper
• A systematic review and meta-analysis of effects of spironolactone on blood pressure, glucose, lipids, renal function, fibrosis and inflammation in patients with hypertension and diabetes

  2021cites this paper
• Exosomes and exosomal cargo in urinary extracellular vesicles: novel potential biomarkers for mineralocorticoid-receptor-associated hypertension

  2021cites this paper
• Efficacy of esaxerenone—a nonsteroidal mineralocorticoid receptor blocker—on nocturnal hypertension

  2021cites this paper
• Development of a New Chemiluminescent Enzyme Immunoassay Using a Two-Step Sandwich Method for Measuring Aldosterone Concentrations

  2021cites this paper
• Effect of spironolactone on cardiovascular morbidity and mortality in patients with hypertension and glucose metabolism disorders (ESCAM): a study protocol for a pragmatic randomised controlled trial

  2020cites this paper
• The importance of the epithelial sodium channel in determining salt sensitivity in people of African origin

  2020cites this paper
• Recent Research Advances in Renin-Angiotensin-Aldosterone System Receptors

  2020cites this paper
• Aldosterone renin ratio and chronic kidney disease

  2020cites this paper
• Lysine-Specific Demethylase-1 Deficiency Increases Agonist Signaling Via the Mineralocorticoid Receptor

  2020cites this paper
• Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension

  2020cites this paper
• Antihypertensive power of Naringenin is mediated via attenuation of mineralocorticoid receptor (MCR)/ angiotensin converting enzyme (ACE)/ kidney injury molecule (Kim-1) signaling pathway.

  2020cites this paper
• Reply: Suspected Borderline Aldosteronism in Hypertension: The Next Target?

  2020cites this paper
• Suspected Borderline Aldosteronism in Hypertension: The Next Target?

  2020cites this paper
• [Pharmacological profile, clinical efficacy, and safety of esaxerenone (Minnebro® tablets 1.25 mg, 2.5 mg, 5 mg)].

  2020cites this paper
• Novel antihypertensive action of rutin is mediated via inhibition of angiotensin converting enzyme/mineralocorticoid receptor/angiotensin 2 type 1 receptor (ATR1) signaling pathways in uninephrectomized hypertensive rats.

  2020cites this paper
• Study of the role of skin lymphatics in electrolyte and blood pressure regulation

  2020cites this paper
• Effect of the Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, on Nocturnal Hypertension: A Post Hoc Analysis of the ESAX-HTN Study

  2020cites this paper
• Role of the vascular endothelial sodium channel activation in the genesis of pathologically increased cardiovascular stiffness.

  2020cites this paper
• Reply

  2020cites this paper
• Aldosterone induces albuminuria via matrix metalloproteinase-dependent damage of the endothelial glycocalyx.

  2019cites this paper
• Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study).

  2019cites this paper
• Improving obesity and blood pressure

  2019cites this paper
• Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study

  2019cites this paper
• Absolute Bioavailability of Esaxerenone and Food Effects on its Pharmacokinetics After a Single Oral Dose in Healthy Japanese Subjects: An Open-Label Crossover Study

  2019cites this paper
• Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study

  2019cites this paper
• High Prevalence of Diabetes in Patients With Primary Aldosteronism (PA) Associated With Subclinical Hypercortisolism and Prediabetes More Prevalent in Bilateral Than Unilateral PA: A Large, Multicenter Cohort Study in Japan

  2019cites this paper
• Role of Pendrin in the Pathophysiology of Aldosterone-Induced Hypertension.

  2019cites this paper
• Intestinal Mineralocorticoid Receptor Contributes to Epithelial Sodium Channel–Mediated Intestinal Sodium Absorption and Blood Pressure Regulation

  2018cites this paper
• Pathophysiological mechanisms of mineralocorticoid receptor-dependent cardiovascular and chronic kidney disease

  2018cites this paper
• The Role of Aldosterone in Hypertension and Related Morbidities

  2018cites this paper
• Epidermal growth factor receptor/extracellular signal-regulated kinase pathway enhances mineralocorticoid receptor transcriptional activity through protein stabilization.

  2018cites this paper
• Resistant Hypertension in Adults With Type 1 or 2 Diabetes: A Structured Diagnostic Approach.

  2018cites this paper
• Resistant Hypertension in Chronic Kidney Disease

  2017cites this paper
• Pathophysiological Insights in Resistant Hypertension

  2017cites this paper
• High Glucose Stimulates Mineralocorticoid Receptor Transcriptional Activity Through the Protein Kinase C β Signaling.

  2017cites this paper
• Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists

  2017influential citation
• Secondary Causes: Work-Up and Its Specificities in CKD: Influence of Autonomic Dysfunction

  2017cites this paper
• Association of Mineralocorticoid Receptor Polymorphism I180V With Left Ventricular Hypertrophy in Resistant Hypertension.

  2016cites this paper
• Context-dependent mechanisms modulating aldosterone signaling in the kidney

  2016cites this paper
• Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?

  2016cites this paper
• ROLES OF OXIDATIVE STRESS AND THE MINERALOCORTICOID RECEPTOR IN CARDIAC PATHOLOGY IN A RAT MODEL OF METABOLIC SYNDROME

  2015cites this paper
• Primary aldosteronism presenting with an atypical aldosterone-renin ratio in the acute phase of cerebral hemorrhage.

  2015cites this paper